Semaglutide approval delays in Brazil
Brazil approval for semaglutide is delayed by 3-4 months, which could impact FY27 unit sales guidance of 12 million units.
medium · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lenalidomide shelf-stock adjustment recurrence
A surprise INR 453 crore shelf-stock adjustment hit Q4 revenue; similar customer-driven adjustments could recur.
medium · analyst_questionU.S. generics price erosion
U.S. generics revenue has been flat despite new launches, indicating significant price erosion that may continue.
high · data_observationCAR T and partnered asset discontinuation
Impairment of INR 135 crore on CAR T and INR 93 crore on partnered asset (Immutep) highlights R&D pipeline risk.
low · management_commentary